Since the amount of palbociclib eliminated in urine is 6.9%, renal impairment is not expected to have much impact on palbociclib. However, the Federal Drug Administration (FDA) Guidance recommends a study in subjects with renal impairment when the drug is likely to be used in patients with impaired renal function. Palbociclib is intended for chronic use in cancer patients who may have some degree of impaired renal function.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
31
palbociclib 125 mg oral capsule with food once
palbociclib 125 mg oral capsule with food once
palbociclib 125 mg oral capsule with food once
Avail Clinical Research, LLC
DeLand, Florida, United States
Orlando Clinical Research Center
Orlando, Florida, United States
Prism Research
Saint Paul, Minnesota, United States
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]
AUC (0 - 8)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 8). It is obtained from AUC (0 - t) plus AUC (t - 8).
Time frame: 8 days
Maximum Observed Plasma Concentration (Cmax)
Time frame: 8 days
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)
Time frame: 8 days
Apparent Oral Clearance (CL/F)
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Time frame: 8 days
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame: 8 days
Apparent Volume of Distribution (Vz/F)
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
Time frame: 8 days
Plasma Decay Half-Life (t1/2)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
palbociclib 125 mg oral capsule with food once
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: 8 days
Unbound Apparent Oral Clearance (CLu/F)
Clearance of unbound drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the oral bioavailability. Unbound drug clearance is a quantitative measure of the rate at which an unbound drug substance is removed from the blood.
Time frame: 8 days
"Unbound Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)u]"
AUC (0 - ∞)u= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞)u for unbound drug. It is obtained from AUC (0 - t)u plus AUC (t - ∞)u for unbound drug.
Time frame: 8 days
Unbound Maximum Observed Plasma Concentration (Cmaxu)
Cmaxu is the highest measured unbound plasma concentration during the dosing interval.
Time frame: 8 days
"Unbound Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClastu)"
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClastu) for unbound drug.
Time frame: 8 days
fraction of unbound drug in plasma (fu)
fraction of drug in plasma or tissues that is not bound to plasma or tissue proteins.
Time frame: 8 days
Unbound Apparent Volume of Distribution (Vzu/F)
Unbound Volume of distribution is defined as the theoretical volume in which the total unbound amount of drug would need to be uniformly distributed to produce the desired unbound plasma concentration of a drug. Unbound Apparent volume of distribution after oral dose (Vzu/F) is influenced by the fraction absorbed.
Time frame: 8 days